Results 41 to 50 of about 20,070 (218)

Selective loss of GABAB receptors in orexin/hypocretin-producing neurons results in disrupted sleep/wakefulness architecture [PDF]

open access: yes, 2007
We generated mice with a selective loss of GABAB receptors in orexin neurons. Orexin neurons in these GABAB1<sup>-/-(orexin)</sup> mice showed reduced responsiveness to GABA<sub>A</sub> receptor agonists due to a ...
Ken-ichi Yagami   +10 more
core  

A rare genetic variant in the cleavage site of prepro-orexin is associated with idiopathic hypersomnia

open access: yesnpj Genomic Medicine, 2022
Idiopathic hypersomnia (IH) is a rare, heterogeneous sleep disorder characterized by excessive daytime sleepiness. In contrast to narcolepsy type 1, which is a well-defined type of central disorders of hypersomnolence, the etiology of IH is poorly ...
Taku Miyagawa   +43 more
doaj   +1 more source

Therapeutic Prospects of Ketamine for Cataplexy in Narcolepsy Type 1: Evidence from a Human Case and a Murine Model

open access: yesAnnals of Neurology, EarlyView.
Narcolepsy type 1 is characterized by cataplexy, for which current treatments targeting monoaminergic, histaminergic, and GABAergic pathways may be ineffective or poorly tolerated. We report the case of a 34‐year‐old man with narcolepsy type 1, intolerant to standard therapies, who experienced marked and sustained cataplexy reduction with morning ...
Francois Ricordeau   +8 more
wiley   +1 more source

Von In‐Silico bis In‐Cerebro – Entwicklung des Orexinrezeptor Antagonisten „Photorexant“ zur Photomodulation In Vitro und im Gehirn der Maus

open access: yesAngewandte Chemie, EarlyView.
Durch einen strukturbasierten Designansatz wurden photoschaltbare Derivate des von der FDA zugelassenen Arzneistoffes Suvorexant entwickelt, gedockt, synthetisiert und pharmakologisch an den Orexin‐1‐ und 2‐Rezeptoren (OX1R und OX2R) charakterisiert.
Marcus Angermann   +10 more
wiley   +1 more source

Orexin-A Exerts Neuroprotective Effects via OX1R in Parkinson’s Disease

open access: yesFrontiers in Neuroscience, 2018
Parkinson’s disease (PD) is a common neurodegenerative disorder characterized by progressive and selective death of dopaminergic neurons. Orexin-A is involved in many biological effects of the body.
Mei-Fang Liu   +8 more
doaj   +1 more source

In Silico to In Cerebro—Development of the Orexin Receptor Antagonist “Photorexant” for Photomodulation In Vitro and in Mouse Brains

open access: yesAngewandte Chemie International Edition, EarlyView.
Following a structure‐based design approach, photoswitchable derivatives of the FDA‐approved drug suvorexant were designed, docked, synthesized, and characterized pharmacologically at the orexin 1 and 2 receptors (OX1R and OX2R). Optimized “photorexant” showed up to an 11‐fold difference in IC50 between photoisomers, enabled dynamic and reversible ...
Marcus Angermann   +10 more
wiley   +1 more source

Stress induces analgesia via orexin 1 receptor-initiated endocannabinoid/CB1 signaling in the mouse periaqueductal gray

open access: yes, 2017
The orexin system consists of orexin A/hypocretin 1 and orexin B/hypocretin 2, and OX1 and OX2 receptors. Our previous electrophysiological study showed that orexin A in the rat ventrolateral periaqueductal gray (vlPAG) induced antinociception via an OX1
邱麗珠   +1 more
core   +1 more source

Research progress on the mechanism of orexin in pain regulation in different brain regions

open access: yesOpen Life Sciences, 2021
Orexin is a neuropeptide that is primarily synthesized and secreted by the lateral hypothalamus (LH) and includes two substances derived from the same precursor (orexin A [OXA] and orexin B [OXB]).
Kang Xianhui   +4 more
doaj   +1 more source

Activation of orexin-2 receptors in the Kӧlliker-Fuse nucleus of anesthetized mice leads to transient slowing of respiratory rate

open access: yesFrontiers in Physiology, 2022
Orexins are neuropeptides originating from the hypothalamus that serve broad physiological roles, including the regulation of autonomic function, sleep-wake states, arousal and breathing.
Adrienn G. Varga   +6 more
doaj   +1 more source

Plasma and breast milk pharmacokinetics of suvorexant in healthy lactating women

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim This paper aims to evaluate the plasma and breast milk pharmacokinetics of suvorexant, an orexin receptor antagonist used to treat insomnia at a maximum dose of 20 mg, in healthy lactating women. Methods The paper reports on an open‐label Phase 1 study in 12 healthy lactating women.
Jacqueline McCrea   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy